STOCK TITAN

Soligenix Invited to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Soligenix (Nasdaq: SNGX), a late-stage biopharmaceutical company focusing on rare diseases with unmet medical needs, has announced its participation in three upcoming investor conferences. The company will provide corporate updates at the following events:

  • 2024 Maxim Healthcare Virtual Summit on October 17, 2024
  • ThinkEquity Conference on October 30, 2024
  • Spartan Capital Investor Conference 2024 on November 4, 2024

Key members of Soligenix management will be available for one-on-one meetings during these conferences. Investors unable to attend can schedule meetings by contacting ir@soligenix.com. For more information on each conference, interested parties can visit the respective conference websites provided in the announcement.

Soligenix (Nasdaq: SNGX), un'azienda biofarmaceutica in fase avanzata focalizzata sulle malattie rare con bisogni medici insoddisfatti, ha annunciato la sua partecipazione a tre prossime conferenze per investitori. L'azienda fornirà aggiornamenti aziendali nei seguenti eventi:

  • Maxim Healthcare Virtual Summit 2024 il 17 ottobre 2024
  • ThinkEquity Conference il 30 ottobre 2024
  • Spartan Capital Investor Conference 2024 il 4 novembre 2024

I membri chiave della direzione di Soligenix saranno disponibili per incontri individuali durante queste conferenze. Gli investitori che non possono partecipare possono programmare incontri contattando ir@soligenix.com. Per ulteriori informazioni su ciascuna conferenza, le parti interessate possono visitare i rispettivi siti web delle conferenze forniti nell'annuncio.

Soligenix (Nasdaq: SNGX), una empresa biofarmacéutica en etapa avanzada centrada en enfermedades raras con necesidades médicas no satisfechas, ha anunciado su participación en tres próximas conferencias para inversores. La compañía proporcionará actualizaciones corporativas en los siguientes eventos:

  • 2024 Maxim Healthcare Virtual Summit el 17 de octubre de 2024
  • ThinkEquity Conference el 30 de octubre de 2024
  • Spartan Capital Investor Conference 2024 el 4 de noviembre de 2024

Los miembros clave de la gestión de Soligenix estarán disponibles para reuniones uno a uno durante estas conferencias. Los inversores que no puedan asistir pueden programar reuniones contactando a ir@soligenix.com. Para más información sobre cada conferencia, las partes interesadas pueden visitar los respectivos sitios web de las conferencias indicados en el anuncio.

Soligenix (Nasdaq: SNGX)은 미충족 의료 수요가 있는 희귀 질환에 초점을 맞춘 후기 단계의 바이오 제약 회사로, 다가오는 세 개의 투자자 회의에 참여할 것이라고 발표했습니다. 회사는 다음 이벤트에서 기업 업데이트를 제공할 예정입니다:

  • 2024 Maxim Healthcare Virtual Summit 2024년 10월 17일
  • ThinkEquity Conference 2024년 10월 30일
  • Spartan Capital Investor Conference 2024년 11월 4일

Soligenix 경영진의 핵심 멤버들이 이 회의 동안 1:1 미팅을 위해 대기하고 있습니다. 참석할 수 없는 투자자들은 ir@soligenix.com으로 연락하여 미팅을 예약할 수 있습니다. 각 회의에 대한 추가 정보는 발표된 회의 웹사이트를 방문해 주시기 바랍니다.

Soligenix (Nasdaq: SNGX), une entreprise biopharmaceutique en phase avancée axée sur les maladies rares avec des besoins médicaux non satisfaits, a annoncé sa participation à trois prochaines conférences pour investisseurs. L'entreprise fournira des mises à jour sur sa stratégie lors des événements suivants :

  • Sommet Virtuel Maxim Healthcare 2024 le 17 octobre 2024
  • Conférence ThinkEquity le 30 octobre 2024
  • Conférence des Investisseurs Spartan Capital 2024 le 4 novembre 2024

Les membres clés de la direction de Soligenix seront disponibles pour des réunions individuelles lors de ces conférences. Les investisseurs qui ne peuvent pas assister peuvent planifier des réunions en contactant ir@soligenix.com. Pour plus d'informations sur chaque conférence, les parties intéressées peuvent visiter les sites web respectifs des conférences mentionnés dans l'annonce.

Soligenix (Nasdaq: SNGX), ein biopharmazeutisches Unternehmen in der Spätphase, das sich auf seltene Krankheiten mit unbefriedigtem medizinischen Bedarf konzentriert, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird auf den folgenden Veranstaltungen Unternehmensupdates bereitstellen:

  • Maxim Healthcare Virtual Summit 2024 am 17. Oktober 2024
  • ThinkEquity Conference am 30. Oktober 2024
  • Spartan Capital Investor Conference 2024 am 4. November 2024

Wichtige Mitglieder des Managements von Soligenix werden während dieser Konferenzen für persönliche Gespräche zur Verfügung stehen. Investoren, die nicht teilnehmen können, können Meetings vereinbaren, indem sie ir@soligenix.com kontaktieren. Für weitere Informationen zu jeder Konferenz können Interessierte die jeweiligen Konferenz-Webseiten besuchen, die in der Ankündigung bereitgestellt wurden.

Positive
  • None.
Negative
  • None.

PRINCETON, N.J., Oct. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will be providing a corporate update at the upcoming investor conferences on the dates below.

Key members of Soligenix management will hold one-on-one meetings throughout the conferences. If you are unable to attend the conferences and would like to schedule a meeting with management, please contact ir@soligenix.com.

About Soligenix

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet's Disease.

Our Public Health Solutions business segment includes development programs for RiVax®, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).

For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.

This press release may contain forward-looking statements that reflect Soligenix's current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations, clinical trial enrollment, the expected timing for closing the offering described herein and the intended use of proceeds therefrom. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements, and include the expected amount and use of proceeds from the offering and the expected closing date of the offering. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that the second HyBryte™ (SGX301) Phase 3 clinical trial will be successful or that a marketing authorization from the FDA or EMA will be granted. Additionally, although the EMA has agreed to the key design components of the second HyBryte™ (SGX301) Phase 3 clinical trial, no assurance can be given that the Company will be able to modify the development path to adequately address the FDA's concerns or that the FDA will not require a longer duration comparative study. Notwithstanding the result in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 2a clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Further, there can be no assurance that RiVax® will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax®. Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/soligenix-invited-to-present-at-upcoming-investor-conferences-302277476.html

SOURCE SOLIGENIX, INC.

FAQ

What investor conferences will Soligenix (SNGX) attend in October and November 2024?

Soligenix will attend three investor conferences: the 2024 Maxim Healthcare Virtual Summit on October 17, the ThinkEquity Conference on October 30, and the Spartan Capital Investor Conference 2024 on November 4, 2024.

How can investors schedule meetings with Soligenix (SNGX) management if they can't attend the conferences?

Investors unable to attend the conferences can schedule meetings with Soligenix management by contacting ir@soligenix.com.

What is the focus of Soligenix (SNGX) as a biopharmaceutical company?

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Where can I find more information about the investor conferences Soligenix (SNGX) is attending?

More information about the conferences can be found on their respective websites, which are provided in the company's announcement.

Soligenix, Inc.

NASDAQ:SNGX

SNGX Rankings

SNGX Latest News

SNGX Stock Data

8.26M
2.28M
0.03%
3.97%
5.89%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PRINCETON